We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$389M
AUM Growth
-$20.8M
Cap. Flow
+$19.4M
Cap. Flow %
4.98%
Top 10 Hldgs %
98.26%
Holding
12
New
1
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$12.8M
2
OCS icon
Oculis Holding
OCS
+$6.61M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$154M 39.54%
2,346,630
– –
SPRY icon
2
ARS Pharmaceuticals
SPRY
$591M
$50.5M 12.97%
4,012,903
– –
MLYS icon
3
Mineralys Therapeutics
MLYS
$2.41B
$49.7M 12.76%
3,127,933
+1,111,111
+55% +$12.8M
ZBIO
4
Zenas BioPharma
ZBIO
$2.05B
$38.8M 9.97%
4,911,539
– –
CRSP icon
5
CRISPR Therapeutics
CRSP
$5.23B
$35.7M 9.17%
1,048,951
– –
DSGN icon
6
Design Therapeutics
DSGN
$915M
$25.2M 6.47%
6,526,476
– –
ALMS
7
Alumis Inc
ALMS
$3.23B
$12M 3.09%
1,959,896
– –
OCS icon
8
Oculis Holding
OCS
$708M
$6.14M 1.58%
+322,500
New +$6.61M
NKTX icon
9
Nkarta
NKTX
$167M
$6.13M 1.58%
3,333,333
– –
ORKA
10
Oruka Therapeutics
ORKA
$6.31B
$4.42M 1.13%
430,330
– –
KALA icon
11
KALA BIO
KALA
$16.3M
$3.43M 0.88%
11,979
– –
ENGN icon
12
enGene Therapeutics
ENGN
$122M
$3.35M 0.86%
747,750
– –

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, SR One Capital Management held 12 positions worth $389M, down 5.1% from $410M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

SR One Capital Management deployed $19.4M of net new capital in Q1 2025, opening 1 new position and adding to 1 existing holding. Its largest new stake was Oculis Holding: 322,500 shares worth $6.14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q1 2025 buy was Oculis Holding: 322,500 shares worth $6.14M.
  • SR One Capital Management added most to Mineralys Therapeutics in Q1 2025, an estimated $12.8M increase.
  • SR One Capital Management's ten largest holdings make up 98% of its $389M portfolio in Q1 2025.
  • SR One Capital Management opened 1 new position and closed 0 in Q1 2025.
  • SR One Capital Management's portfolio value fell 5.1% quarter-over-quarter to $389M.

Based on SR One Capital Management's 13F filing for Q1 2025, filed 13 May 2025.